Profile data is unavailable for this security.
About the company
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Company’s main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.
- Revenue in CNY (TTM)14.01bn
- Net income in CNY1.97bn
- Incorporated2001
- Employees7.92k
- LocationShandong Buchang Pharmaceuticals Co LtdNo. 369, Zhonghua West RoadHEZE 274009ChinaCHN
- Phone+86 5 305299167
- Fax+86 5 305299286
- Websitehttp://www.buchang.com/
More ▼
Mergers & acquisitions
| Acquired company | 603858:SHH since announced | Transaction value |
|---|---|---|
| Shanghai Hepu Medical Technology Co Ltd | -- | 20.26m |
Data delayed at least 15 minutes, as of Jun 03 2020 08:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.76bn | -339.51m | 14.43bn | 9.51k | -- | 2.88 | -- | 2.14 | -0.1301 | -0.1301 | 2.51 | 1.88 | 0.6405 | 1.54 | 4.61 | 710,455.50 | -2.47 | 4.72 | -4.21 | 7.52 | 72.11 | 65.61 | -3.85 | 7.20 | 0.9115 | 5.19 | 0.3526 | 60.83 | -3.56 | 13.57 | -142.40 | -- | -8.94 | -- |
| Zhejiang Medicine Co., Ltd. | 6.93bn | 358.25m | 15.82bn | 6.42k | 43.16 | 1.96 | -- | 2.28 | 0.3798 | 0.3798 | 7.14 | 8.36 | 0.6651 | 3.34 | 4.92 | 1,079,234.00 | 2.95 | 3.18 | 3.84 | 4.01 | 38.81 | 32.97 | 4.43 | 4.98 | 1.86 | -- | 0.1014 | 86.86 | 2.70 | 7.83 | -5.97 | 15.09 | -10.37 | 75.54 |
| Tasly Pharmaceutical Group Co Ltd | 18.38bn | 848.10m | 22.34bn | 9.24k | 26.24 | 1.96 | -- | 1.22 | 0.563 | 0.563 | 12.18 | 7.56 | 0.7507 | 5.31 | 2.07 | 1,990,227.00 | 3.44 | 6.90 | 5.41 | 12.61 | 29.77 | 35.53 | 4.59 | 8.40 | 1.70 | 2.99 | 0.4257 | 38.63 | 5.61 | 8.60 | -35.19 | -6.05 | -0.6484 | -- |
| Shandong Buchang Pharmaceuticals Co Ltd | 14.01bn | 1.97bn | 27.92bn | 7.92k | 13.62 | 1.94 | -- | 1.99 | 1.80 | 1.80 | 12.79 | 12.61 | 0.6882 | 1.72 | 12.04 | 1,768,453.00 | 9.73 | 12.18 | 13.08 | 18.07 | 80.79 | 82.86 | 14.14 | 16.44 | 0.8984 | 25.45 | 0.174 | -- | 4.32 | 6.65 | 3.05 | 8.01 | 26.44 | -- |
| Jointown Pharmaceutical Group Co Ltd | 102.01bn | 1.84bn | 34.66bn | 25.80k | 18.44 | 1.90 | -- | 0.3398 | 1.00 | 1.00 | 55.38 | 9.74 | 1.49 | 6.41 | 4.33 | 3,954,377.00 | 3.05 | 2.63 | 10.05 | 7.79 | 8.58 | 8.34 | 2.04 | 1.68 | 0.9513 | 3.15 | 0.5928 | 62.64 | 14.19 | 19.36 | 39.51 | 22.77 | 4.74 | -- |
Data as of Jun 03 2020. Currency figures normalised to Shandong Buchang Pharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
1.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Southern Asset Management Co., Ltd.as of 31 Dec 2019 | 5.82m | 0.51% |
| Goldman Sachs Asset Management Internationalas of 29 Feb 2020 | 3.95m | 0.35% |
| Goldman Sachs Asset Management LPas of 29 Feb 2020 | 1.85m | 0.16% |
| Robeco Institutional Asset Management BVas of 31 Mar 2020 | 1.21m | 0.11% |
| GF Fund Management Co., Ltd.as of 31 Dec 2019 | 1.16m | 0.10% |
| China Asset Management Co., Ltd.as of 31 Dec 2019 | 851.68k | 0.08% |
| CPIC Fund Management Co. Ltd.as of 30 Jun 2019 | 815.48k | 0.07% |
| BlackRock Advisors (UK) Ltd.as of 06 May 2020 | 667.33k | 0.06% |
| The Vanguard Group, Inc.as of 30 Apr 2020 | 658.80k | 0.06% |
| Mellon Investments Corp.as of 07 May 2020 | 528.37k | 0.05% |
More ▼
Data from 30 Jun 2019 - 26 May 2020Source: FactSet Research Systems Inc.
